Alexander Bukreyev

List of Publications by Year
in descending order

132	8,139	41323	56687
papers	citations	49 h-index	83 g-index

143	143	143	9776
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	0.9	407
2	Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6641-6646.	3.3	390
3	Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9804-9809.	3.3	372
4	Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium. Journal of Virology, 2005, 79, 1113-1124.	1.5	259
5	Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet, The, 2004, 363, 2122-2127.	6.3	252
6	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	0.9	224
7	Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees. Journal of Virology, 1999, 73, 3438-3442.	1.5	206
8	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	0.9	184
9	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	0.9	173
10	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
11	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell, 2016, 164, 392-405.	13.5	160
12	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	0.9	153
13	The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes. Journal of Virology, 2008, 82, 12191-12204.	1.5	143
14	Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus. Journal of Virology, 2007, 81, 6379-6388.	1.5	142
15	SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 712-720.	5.2	136
16	Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science, 2016, 352, aad7993.	6.0	132
17	Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. Cell, 2015, 160, 893-903.	13.5	130
18	Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9788-9793.	3.3	126

#	Article	IF	Citations
19	Respiratory Syncytial Virus Infection Sensitizes Cells to Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Journal of Virology, 2003, 77, 9156-9172.	1.5	121
20	Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. Journal of Infectious Diseases, 2018, 217, 451-455.	1.9	119
21	Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates. Journal of Virology, 2005, 79, 13275-13284.	1.5	107
22	Nonstructural Proteins 1 and 2 of Respiratory Syncytial Virus Suppress Maturation of Human Dendritic Cells. Journal of Virology, 2008, 82, 8780-8796.	1.5	100
23	Nonsegmented Negative-Strand Viruses as Vaccine Vectors. Journal of Virology, 2006, 80, 10293-10306.	1.5	98
24	Respiratory Syncytial Virus Interferon Antagonist NS1 Protein Suppresses and Skews the Human T Lymphocyte Response. PLoS Pathogens, 2011, 7, e1001336.	2.1	98
25	Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. MBio, 2017, 8, .	1.8	97
26	Immunization of Primates with a Newcastle Disease Virus-Vectored Vaccine via the Respiratory Tract Induces a High Titer of Serum Neutralizing Antibodies against Highly Pathogenic Avian Influenza Virus. Journal of Virology, 2007, 81, 11560-11568.	1.5	92
27	A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs against a Lethal-Dose Ebola Virus Challenge. Journal of Virology, 2006, 80, 2267-2279.	1.5	90
28	Newcastle Disease Virus-Vectored Vaccines Expressing the Hemagglutinin or Neuraminidase Protein of H5N1 Highly Pathogenic Avian Influenza Virus Protect against Virus Challenge in Monkeys. Journal of Virology, 2010, 84, 1489-1503.	1.5	86
29	The Lack of Maturation of Ebola Virus-Infected Dendritic Cells Results from the Cooperative Effect of at Least Two Viral Domains. Journal of Virology, 2013, 87, 7471-7485.	1.5	84
30	Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine, 2010, 29, 17-25.	1.7	80
31	Rational Design of Live-Attenuated Recombinant Vaccine Virus for Human Respiratory Syncytial Virus by Reverse Genetics. Advances in Virus Research, 1999, 54, 423-451.	0.9	78
32	ICTV Virus Taxonomy Profile: Filoviridae. Journal of General Virology, 2019, 100, 911-912.	1.3	78
33	Role of Protein Phosphatase 1 in Dephosphorylation of Ebola Virus VP30 Protein and Its Targeting for the Inhibition of Viral Transcription. Journal of Biological Chemistry, 2014, 289, 22723-22738.	1.6	76
34	Characteristics of Filoviridae: Marburg and Ebola Viruses. Die Naturwissenschaften, 1999, 86, 8-17.	0.6	75
35	Granulocyte-Macrophage Colony-Stimulating Factor Expressed by Recombinant Respiratory Syncytial Virus Attenuates Viral Replication and Increases the Level of Pulmonary Antigen-Presenting Cells. Journal of Virology, 2001, 75, 12128-12140.	1.5	74
36	Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral Research, 2018, 158, 288-302.	1.9	73

#	Article	IF	Citations
37	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Immunity, 2020, 52, 388-403.e12.	6.6	71
38	Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion. MBio, 2017, 8, .	1.8	70
39	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	0.9	70
40	Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2â€“MPER region. Nature Microbiology, 2018, 3, 670-677.	5.9	68
41	Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. Journal of Clinical Investigation, 2015, 125, 3241-3255.	3.9	67
42	Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Reports, 2018, 24, 1802-1815.e5.	2.9	64
43	Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Frontiers in Microbiology, 2016, 7, 1765.	1.5	62
44	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	0.9	62
45	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity, 2018, 49, 363-374.e10.	6.6	61
46	Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology, 2009, 383, 348-361.	1.1	59
47	High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication. ACS Infectious Diseases, 2015, 1, 380-387.	1.8	59
48	Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology, 2009, 385, 169-182.	1.1	58
49	Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathogens, 2017, 13, e1006397.	2.1	58
50	Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1Î² Responses. Journal of Virology, 2015, 89, 8974-8981.	1.5	52
51	Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions. Journal of Virology, 2017, 91, .	1.5	52
52	Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer Cells. Journal of Virology, 2010, 84, 4073-4082.	1.5	50
53	The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and Complement. Journal of Virology, 2012, 86, 10880-10884.	1.5	50
54	Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. Journal of Virology, 2015, 89, 7567-7583.	1.5	50

#	Article	IF	Citations
55	Newcastle disease virus as a vaccine vector for humans. Current Opinion in Molecular Therapeutics, 2008, 10, 46-55.	2.8	50
56	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	1.5	49
57	Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. Cell Host and Microbe, 2020, 27, 976-991.e11.	5.1	43
58	Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Journal of Virology, 2016, 90, 3890-3901.	1.5	41
59	The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge. MBio, 2017, 8, .	1.8	41
60	The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host and Microbe, 2018, 23, 101-109.e4.	5.1	40
61	The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response. Journal of Virology, 2006, 80, 5958-5967.	1.5	39
62	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications, 2021, 12, 6097.	5.8	38
63	Neonatal antibody responses are attenuated by interferon-Î³ produced by NK and T cells during RSV infection. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5576-5581.	3.3	36
64	Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis. MBio, 2018, 9, .	1.8	35
65	The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses. PLoS Pathogens, 2016, 12, e1006031.	2.1	35
66	A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology, 2008, 377, 255-264.	1.1	34
67	Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection. PLoS Pathogens, 2019, 15, e1008068.	2.1	34
68	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity, 2021, 54, 815-828.e5.	6.6	34
69	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2â€“specific monoclonal antibody CR3022. JCI Insight, 2021, 6, .	2.3	34
70	Effects of Human Respiratory Syncytial Virus, Metapneumovirus, Parainfluenza Virus 3 and Influenza Virus on CD4+ T Cell Activation by Dendritic Cells. PLoS ONE, 2010, 5, e15017.	1.1	34
71	Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. Journal of Clinical Virology, 2021, 145, 105024.	1.6	33
72	A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication. Antiviral Research, 2018, 150, 193-201.	1.9	32

#	Article	IF	Citations
73	Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. Trends in Microbiology, 2019, 27, 8-16.	3.5	32
74	Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19. Journal of Immunology, 2021, 206, 2785-2790.	0.4	31
75	The Cysteine-Rich Region and Secreted Form of the Attachment G Glycoprotein of Respiratory Syncytial Virus Enhance the Cytotoxic T-Lymphocyte Response despite Lacking Major Histocompatibility Complex Class I-Restricted Epitopes. Journal of Virology, 2006, 80, 5854-5861.	1.5	30
76	Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nature Structural and Molecular Biology, 2019, 26, 204-212.	3.6	30
77	Virally Delivered Cytokines Alter the Immune Response to Future Lung Infections. Journal of Virology, 2007, 81, 13105-13111.	1.5	28
78	Delivery of Cytokines by Recombinant Virus in Early Life Alters the Immune Response to Adult Lung Infection. Journal of Virology, 2010, 84, 5294-5302.	1.5	28
79	Effect of Coexpression of Interleukin-2 by Recombinant Respiratory Syncytial Virus on Virus Replication, Immunogenicity, and Production of Other Cytokines. Journal of Virology, 2000, 74, 7151-7157.	1.5	27
80	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nature Biotechnology, 2022, 40, 1270-1275.	9.4	27
81	Expression of Interleukin-4 by Recombinant Respiratory Syncytial Virus Is Associated with Accelerated Inflammation and a Nonfunctional Cytotoxic T-Lymphocyte Response following Primary Infection but Not following Challenge with Wild-Type Virus. Journal of Virology, 2005, 79, 9515-9526.	1.5	26
82	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell, 2022, 185, 995-1007.e18.	13.5	26
83	Respiratory Syncytial Virus Can Tolerate an Intergenic Sequence of at Least 160 Nucleotides with Little Effect on Transcription or Replication In Vitro and In Vivo. Journal of Virology, 2000, 74, 11017-11026.	1.5	25
84	A BSL-4 High-Throughput Screen Identifies Sulfonamide Inhibitors of Nipah Virus. Assay and Drug Development Technologies, 2014, 12, 155-161.	0.6	24
85	Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nature Communications, 2019, 10, 1788.	5.8	24
86	Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathogens, 2021, 17, e1009383.	2.1	24
87	Disabling of lymphocyte immune response by Ebola virus. PLoS Pathogens, 2018, 14, e1006932.	2.1	23
88	Attenuated activation of pulmonary immune cells in mRNA-1273â€“vaccinated hamsters after SARS-CoV-2 infection. Journal of Clinical Investigation, 2021, 131, .	3.9	23
89	A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35â€“NP Interface. ACS Infectious Diseases, 2017, 3, 190-198.	1.8	22
90	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	1.5	22

#	Article	IF	Citations
91	Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Reports, 2021, 35, 108984.	2.9	22
92	Ebola vaccineâ€“induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Science Translational Medicine, 2021, 13, .	5.8	22
93	Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell, 2021, 184, 5593-5607.e18.	13.5	21
94	Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 andÂFibroblast Growth Factors Than Mild Symptomatic COVID-19. Frontiers in Immunology, 2022, 13, 821730.	2.2	21
95	What Are the Risksâ€”Hypothetical and Observedâ€”of Recombination Involving Live Vaccines and Vaccine Vectors Based on Nonsegmented Negative-Strain RNA Viruses?. Journal of Virology, 2008, 82, 9805-9806.	1.5	20
96	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports, 2021, 37, 109784.	2.9	20
97	Phosphorylated VP30 of Marburg Virus Is a Repressor of Transcription. Journal of Virology, 2018, 92, .	1.5	19
98	A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. Npj Vaccines, 2021, 6, 91.	2.9	19
99	Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. Cell Reports, 2021, 35, 109086.	2.9	18
100	More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16987-16991.	3.3	17
101	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	2.7	17
102	Species-Specific Evolution of Ebola Virus during Replication in Human and Bat Cells. Cell Reports, 2020, 32, 108028.	2.9	17
103	Topoisomerase III-Î² is required for efficient replication of positive-sense RNA viruses. Antiviral Research, 2020, 182, 104874.	1.9	17
104	Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. PLoS Pathogens, 2018, 14, e1007204.	2.1	16
105	Protein Phosphatase 1â€“Targeting Small-Molecule C31 Inhibits Ebola Virus Replication. Journal of Infectious Diseases, 2018, 218, S627-S635.	1.9	14
106	Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition. Frontiers in Microbiology, 2019, 10, 2145.	1.5	14
107	Ebola Virus Produces Discrete Small Noncoding RNAs Independently of the Host MicroRNA Pathway Which Lack RNA Interference Activity in Bat and Human Cells. Journal of Virology, 2020, 94, .	1.5	14
108	Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions. Journal of Infectious Diseases, 2018, 218, S335-S345.	1.9	13

#	Article	IF	Citations
109	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Journal of Virology, 2019, 93, .	1.5	13
110	Adapting High-Throughput Screening Methods and Assays for Biocontainment Laboratories. Assay and Drug Development Technologies, 2015, 13, 44-54.	0.6	12
111	Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation. Journal of Infectious Diseases, 2018, 218, S327-S334.	1.9	12
112	Discovery of Marburg virus neutralizing antibodies from virus-naÃ¯ve human antibody repertoires using large-scale structural predictions. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31142-31148.	3.3	10
113	Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection. Npj Vaccines, 2020, 5, 78.	2.9	10
114	Expression of immunomodulating molecules by recombinant viruses: can the immunogenicity of live virus vaccines be improved?. Expert Review of Vaccines, 2002, 1, 233-245.	2.0	9
115	Annexin A2 depletion exacerbates the intracerebral microhemorrhage induced by acute rickettsia and Ebola virus infections. PLoS Neglected Tropical Diseases, 2020, 14, e0007960.	1.3	9
116	Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors. Cell Reports, 2018, 24, 1816-1829.	2.9	8
117	Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cellular and Molecular Life Sciences, 2020, 77, 2579-2603.	2.4	8
118	Proximity interactome analysis of Lassa polymerase reveals eRF3a/GSPT1 as a druggable target for host-directed antivirals. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
119	Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication. Cell Reports, 2022, 38, 110544.	2.9	7
120	Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection. Frontiers in Immunology, 2021, 12, 681586.	2.2	6
121	OUP accepted manuscript. Journal of Infectious Diseases, 2018, 218, S418-S422.	1.9	6
122	A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, 47.	2.9	6
123	Ubiquitination of Ebola virus VP35 at lysine 309 regulates viral transcription and assembly. PLoS Pathogens, 2022, 18, e1010532.	2.1	6
124	Intracellular receptor EPAC regulates von Willebrand factor secretion from endothelial cells in a PI3K-/eNOS-dependent manner during inflammation. Journal of Biological Chemistry, 2021, 297, 101315.	1.6	5
125	Effects of Overexpression of the Egyptian Fruit Bat Innate Immune Genes on Filovirus Infections in the Host Cells. Frontiers in Virology, 2021, 1, .	0.7	5
126	Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region. PLoS Pathogens, 2022, 18, e1010518.	2.1	5

#	Article	IF	Citations
127	Filovirus vaccines: what challenges are left?. Expert Review of Vaccines, 2010, 9, 5-8.	2.0	4
128	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. Frontiers in Immunology, 2021, 12, 706757.	2.2	4
129	Proteoform-Specific Insights into Cellular Proteome Regulation. Molecular and Cellular Proteomics, 2016, 15, 3297-3320.	2.5	3
130	Antibody responses to filovirus infections in humans: protective or not?. Lancet Infectious Diseases, The, 2021, 21, e348-e355.	4.6	3
131	Advances in the development of vaccines against Marburg and Ebola viruses. Future Virology, 2007, 2, 537-541.	0.9	1
132	Small Molecule Compounds That Inhibit Antioxidant Response Gene Expression in an Inducer-Dependent Manner. ACS Infectious Diseases, 2020, 6, 489-502.	1.8	1